Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis
Key facts
- Who runs it
- Nterica Bio inc
- Where
- Coronado, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 12 people, planned
- Started
- 5 Nov 2025
- Planned end
- Jun 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- bacteriophage preparation
- Record updated
- 17 August 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Diagnostic definition of acute alcohol-associated hepatitis based on well established standard disease markers
- Able to provide written informed consent (either from patient or patient's legally authorized representative)
- Male and female patients aged ≥18 years and ≤ 70 years of age
- BMI ≥ 20 to ≤ 40 kg/m2
- Enterococcus faecalis testing
- Susceptibility to NTR-101
- Women of child-bearing potential and male patients must agree to use a medically acceptable method of contraception/ birth control throughout the study duration
Who cannot take part
- Participants taking systemic corticosteroids for a specified duration
- Other or concomitant cause(s) of liver disease as a result of other conditions
- Positive urine drug screen
- Any significant systemic or major illness other than liver disease that, in the opinion of the investigator, would preclude the patient from participating in and completing the study or might complicated or exacerbated by the proposed treatments or might confound assessment of investigational product
- Active bacterial or viral infections
- Co-infection with HIV
- Platelet count below specified ranges
- INR and Serum creatinine levels above specified ranges
- If female, known pregnancy, or has a positive serum pregnancy test, or lactating/ breastfeeding
- Participants considered at high risk for alcohol withdrawal according to the clinical institute withdrawal assessment (CIWA-Ar) protocol
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Southern California Research Center, IncCoronado, United StatesContact: Kasey SeyerNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn about the safety and tolerability of NTR-101 in adult participants suffering from acute alcohol-associated hepatitis (AH).
Read full original descriptionShow less
The drug is intended for use in the treatment of AH where the presence of specific strains of E. faecalis play a contributing role.
The main questions it aims to answer are:
Are multiple doses of NTR-101 in participants with acute AH safe and well tolerated? What medical problems do participants have when taking NTR-101? Researchers will administer the drug and monitor participants in an inpatient center.
Participants will:
Be administered multiple ascending dose frequencies of NTR-101 every day for 7 days.
Stay in the clinic for 9 days (7 days of treatment) and present to clinic once every week for checkups and tests for 35 days.
Keep a diary of their symptoms until the checkups and tests are completed.
The 4 groups in the trial
- Cohort 1Existing treatment, for comparison
Dose 1
Treatment: bacteriophage preparation
- Cohort 2Existing treatment, for comparison
Dose 2
Treatment: Bacteriophage preparation
- Cohort 3Existing treatment, for comparison
Dose 3
Treatment: bacteriophage preparation
- Cohort 4Existing treatment, for comparison
Dose 4
Treatment: bacteriophage preparation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1, Open Label Study to Evaluate Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis
- Criteria questions
- Built from NCT06750588, who can take part
- Record updated
- 17 August 2025